{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dovitinib+%28TKI258%29",
    "query": {
      "intervention": "dovitinib (TKI258)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 24,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dovitinib+%28TKI258%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T06:51:37.947Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01888965",
      "title": "Maintenance Dovitinib for Colorectal and Pancreas Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "Dovitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2013-10",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-07-19",
      "last_synced_at": "2026-09-28T06:51:37.947Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01888965"
    },
    {
      "nct_id": "NCT01497392",
      "title": "Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of the Pancreas",
        "Stage III Pancreatic Cancer",
        "Stage IV Pancreatic Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "dovitinib lactate",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "enzyme-linked immunosorbent assay",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2012-03-29",
      "completion_date": "2017-02-07",
      "has_results": false,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-09-28T06:51:37.947Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01497392"
    },
    {
      "nct_id": "NCT01524692",
      "title": "Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenoid Cystic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dovitinib (TKI258)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2012-03",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-09-28T06:51:37.947Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01524692"
    },
    {
      "nct_id": "NCT00958971",
      "title": "Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TKI258",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 43,
      "start_date": "2009-07",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-28T06:51:37.947Z",
      "location_count": 18,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00958971"
    },
    {
      "nct_id": "NCT01528345",
      "title": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dovitinib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Dovitinib Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 97,
      "start_date": "2012-04",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-07-11",
      "last_synced_at": "2026-09-28T06:51:37.947Z",
      "location_count": 18,
      "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01528345"
    },
    {
      "nct_id": "NCT01515969",
      "title": "Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC), Recurrent",
        "Non-small Cell Lung Cancer (NSCLC), Stage IV"
      ],
      "interventions": [
        {
          "name": "Erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Dovitinib lactate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Heather Wakelee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2012-07",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2016-07-12",
      "last_synced_at": "2026-09-28T06:51:37.947Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01515969"
    },
    {
      "nct_id": "NCT02048943",
      "title": "Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duct Cell Adenocarcinoma of the Pancreas",
        "Recurrent Pancreatic Cancer",
        "Stage III Pancreatic Cancer",
        "Stage IV Pancreatic Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "dovitinib lactate",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel albumin-stabilized nanoparticle formulation",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-01-09",
      "last_synced_at": "2026-09-28T06:51:37.947Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02048943"
    },
    {
      "nct_id": "NCT01753713",
      "title": "Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "dovitinib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Manmeet Ahluwalia, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2012-12-20",
      "completion_date": "2017-09-20",
      "has_results": true,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-09-28T06:51:37.947Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01753713"
    },
    {
      "nct_id": "NCT01700270",
      "title": "Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors, Excluding Breast Cancer"
      ],
      "interventions": [
        {
          "name": "dovitinib (TKI258)",
          "type": "DRUG"
        },
        {
          "name": "fluvoxamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2013-05",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2020-12-21",
      "last_synced_at": "2026-09-28T06:51:37.947Z",
      "location_count": 2,
      "location_summary": "The Bronx, New York • San Antonio, Texas",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01700270"
    },
    {
      "nct_id": "NCT01496534",
      "title": "Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matthew Galsky",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2012-01",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-11-27",
      "last_synced_at": "2026-09-28T06:51:37.947Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01496534"
    }
  ]
}